Methotrexate vs alternative disease‐modifying antirheumatic drugs
Pain · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
31 questions · 32 findings · 2 reviews · Musculoskeletal
No studies found 13 · 40.6%GRADE not reported 0 · 0%Very low 2 · 6.3%Low 17 · 53.1%Moderate 0 · 0%High 0 · 0%
Methotrexate vs alternative disease‐modifying antirheumatic drugs
Global well‐being: rated by participants · children and young people with JIA
1 finding from 1 review
- no estimate extracted1 study · 94 participantsLow
Methotrexate vs alternative disease‐modifying antirheumatic drugs
Serious adverse events(4 months) · children and young people with JIA
Methotrexate showed no clear difference in serious adverse events(4 months) compared with alternative disease‐modifying antirheumatic drugs (low certainty).
1 finding from 1 review
- RR 0.14 [0.01, 2.69]1 study · 94 participantsLow
Methotrexate vs alternative disease‐modifying antirheumatic drugs
Withdrawals due to adverse events · children and young people with JIA
Methotrexate showed no clear difference in withdrawals due to adverse events(4 months) compared with alternative disease‐modifying antirheumatic drugs (low certainty).
1 finding from 1 review
- RR 0.33 [0.04, 3.09]1 study · 94 participantsLow
Methotrexate vs placebo
Sustained clinically inactive diseasec · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Methotrexate vs placebo
Function · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Methotrexate vs placebo
Pain on motion · children and young people with JIA
1 finding from 1 review
- no estimate extracted1 study · 114 participantsLow
Methotrexate vs placebo
Global well‐being: rated by participants · children and young people with JIA
Methotrexate showed no clear difference in participant global assessment of well‐being(up to 6 months) compared with placebo (low certainty).
1 finding from 1 review
- RR 1.23 [0.88, 1.72]1 study · 176 participantsLow
Methotrexate vs placebo
Serious adverse events(up to 6 months) · children and young people with JIA
Methotrexate showed no clear difference in serious adverse events(up to 6 months) compared with placebo (low certainty).
1 finding from 1 review
- RR 0.63 [0.04, 8.97]3 studies · 328 participantsLow
Methotrexate vs placebo
Withdrawals due to adverse events · children and young people with JIA
Methotrexate showed no clear difference in withdrawals due to adverse events (up to 6 months) compared with placebo (low certainty).
1 finding from 1 review
- RR 3.46 [0.6, 19.79]3 studies · 328 participantsLow
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone
OutcomesTime frame of absolute effects · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found